6848 logo

RBC Bioscience TPEX:6848 Stock Report

Last Price

NT$18.20

Market Cap

NT$236.2m

7D

2.2%

1Y

12.0%

Updated

18 Dec, 2024

Data

Company Financials

RBC Bioscience Corporation

TPEX:6848 Stock Report

Market Cap: NT$236.2m

6848 Stock Overview

Researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. More details

6848 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth0/6
Past Performance2/6
Financial Health2/6
Dividends4/6

My Notes

Capture your thoughts, links and company narrative

RBC Bioscience Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for RBC Bioscience
Historical stock prices
Current Share PriceNT$18.20
52 Week HighNT$24.60
52 Week LowNT$14.70
Beta0.068
1 Month Change-8.77%
3 Month Change-7.61%
1 Year Change12.00%
3 Year Change-45.52%
5 Year Changen/a
Change since IPO-62.65%

Recent News & Updates

Recent updates

Shareholder Returns

6848TW Life SciencesTW Market
7D2.2%-2.2%0.9%
1Y12.0%-24.2%28.9%

Return vs Industry: 6848 exceeded the TW Life Sciences industry which returned -23.8% over the past year.

Return vs Market: 6848 underperformed the TW Market which returned 28.5% over the past year.

Price Volatility

Is 6848's price volatile compared to industry and market?
6848 volatility
6848 Average Weekly Movement5.7%
Life Sciences Industry Average Movement4.2%
Market Average Movement4.5%
10% most volatile stocks in TW Market7.8%
10% least volatile stocks in TW Market2.1%

Stable Share Price: 6848 has not had significant price volatility in the past 3 months compared to the TW market.

Volatility Over Time: 6848's weekly volatility (6%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995n/an/awww.rbcbioscience.com

RBC Bioscience Corporation researches, develops, manufactures, and sells reagents and devices for life science and molecular diagnosis in Europe, the United States, Asia, Taiwan, Africa, and Australia. It offers molecular biomedical diagnostic and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues; automated nucleic acid extractors; and nucleic acid extraction kits. The company sells its products through distributors.

RBC Bioscience Corporation Fundamentals Summary

How do RBC Bioscience's earnings and revenue compare to its market cap?
6848 fundamental statistics
Market capNT$236.16m
Earnings (TTM)NT$17.27m
Revenue (TTM)NT$194.62m

13.7x

P/E Ratio

1.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
6848 income statement (TTM)
RevenueNT$194.62m
Cost of RevenueNT$106.26m
Gross ProfitNT$88.36m
Other ExpensesNT$71.09m
EarningsNT$17.27m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.33
Gross Margin45.40%
Net Profit Margin8.87%
Debt/Equity Ratio185.5%

How did 6848 perform over the long term?

See historical performance and comparison

Dividends

6.2%

Current Dividend Yield

75%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/18 10:33
End of Day Share Price 2024/12/18 00:00
Earnings2024/06/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

RBC Bioscience Corporation is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution